{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:58:47Z","timestamp":1782316727787,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,3]]},"DOI":"10.7759\/cureus.98370","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:49:09Z","timestamp":1764766149000},"source":"Crossref","is-referenced-by-count":1,"title":["A Hidden Pathway to a Major Concern: The Role of Pyroptosis in Inducing Myocardial Infarction Reperfusion Injury and Emerging Therapeutic Targets"],"prefix":"10.7759","author":[{"given":"Zain  A","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamedanas Mohamedfaruk","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak  M","family":"Qassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor M","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim  K","family":"Al Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Kharoufeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman A","family":"Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan A","family":"Aloti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart Disease and Stroke Statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao CW","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al.. Heart Disease and Stroke Statistics-2022 update: a report from the American Heart Association. Circulation. 2022, 145:e153-639. 10.1161\/CIR.0000000000001052","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001039","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Lawton JS","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, et al.. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e4-e17. 10.1161\/CIR.0000000000001039","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon DM","year":"2007","unstructured":"Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007, 357:1121-35. 10.1056\/NEJMra071667","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62874","article-title":"Myocardial ischemia-reperfusion injury: a neglected therapeutic target","volume":"123","author":"Hausenloy DJ","year":"2013","unstructured":"Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013, 123:92-100. 10.1172\/JCI62874","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"Heusch G","year":"2020","unstructured":"Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020, 17:773-89. 10.1038\/s41569-020-0403-y","journal-title":"Nat Rev Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1124\/pr.113.008300","article-title":"Interaction of risk factors, comorbidities, and comedications with ischemia\/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning","volume":"66","author":"Ferdinandy P","year":"2014","unstructured":"Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia\/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014, 66:1142-74. 10.1124\/pr.113.008300","journal-title":"Pharmacol Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi J","year":"2017","unstructured":"Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017, 42:245-54. 10.1016\/j.tibs.2016.10.004","journal-title":"Trends Biochem Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2070","article-title":"Pyroptosis: host cell death and inflammation","volume":"7","author":"Bergsbaken T","year":"2009","unstructured":"Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009, 7:99-109. 10.1038\/nrmicro2070","journal-title":"Nat Rev Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2006.02.025","article-title":"The role of oxidants and free radicals in reperfusion injury","volume":"70","author":"Zweier JL","year":"2006","unstructured":"Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006, 70:181-90. 10.1016\/j.cardiores.2006.02.025","journal-title":"Cardiovasc Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.08.020","article-title":"Reperfusion injury and reactive oxygen species: the evolution of a concept","volume":"6","author":"Granger DN","year":"2015","unstructured":"Granger DN, Kvietys PR. Reperfusion injury and reactive oxygen species: the evolution of a concept. Redox Biol. 2015, 6:524-51. 10.1016\/j.redox.2015.08.020","journal-title":"Redox Biol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2007","article-title":"Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury","volume":"88","author":"Murphy E","year":"2008","unstructured":"Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008, 88:581-609. 10.1152\/physrev.00024.2007","journal-title":"Physiol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2009.02.021","article-title":"What is the mitochondrial permeability transition pore?","volume":"46","author":"Halestrap AP","year":"2009","unstructured":"Halestrap AP. What is the mitochondrial permeability transition pore?. J Mol Cell Cardiol. 2009, 46:821-31. 10.1016\/j.yjmcc.2009.02.021","journal-title":"J Mol Cell Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2014.09.023","article-title":"The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection","volume":"78","author":"Bernardi P","year":"2015","unstructured":"Bernardi P, Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J Mol Cell Cardiol. 2015, 78:100-6. 10.1016\/j.yjmcc.2014.09.023","journal-title":"J Mol Cell Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2011.38","article-title":"Innate immune signaling in cardiac ischemia","volume":"8","author":"Arslan F","year":"2011","unstructured":"Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol. 2011, 8:292-300. 10.1038\/nrcardio.2011.38","journal-title":"Nat Rev Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.28","article-title":"The inflammatory response in myocardial injury, repair, and remodelling","volume":"11","author":"Frangogiannis NG","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014, 11:255-65. 10.1038\/nrcardio.2014.28","journal-title":"Nat Rev Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505489","article-title":"Cyclosporine before PCI in patients with acute myocardial infarction","volume":"373","author":"Cung TT","year":"2015","unstructured":"Cung TT, Morel O, Cayla G, et al.. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015, 373:1021-31. 10.1056\/NEJMoa1505489","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.081","article-title":"Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial","volume":"67","author":"Ottani F","year":"2016","unstructured":"Ottani F, Latini R, Staszewsky L, et al.. Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol. 2016, 67:365-74. 10.1016\/j.jacc.2015.10.081","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32039-2","article-title":"Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI- 2\/ERIC-PPCI): a single-blind randomised controlled trial","volume":"394","author":"Hausenloy DJ","year":"2019","unstructured":"Hausenloy DJ, Kharbanda RK, M\u00f8ller UK, et al.. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI- 2\/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019, 394:1415-24. 10.1016\/s0140-6736(19)32039-2","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0228-2","article-title":"The gasdermins, a protein family executing cell death and inflammation","volume":"20","author":"Broz P","year":"2020","unstructured":"Broz P, Pelegr\u00edn P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020, 20:143-57. 10.1038\/s41577-019-0228-2","journal-title":"Nat Rev Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind FG","year":"2009","unstructured":"Bauernfeind FG, Horvath G, Stutz A, et al.. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009, 183:787-91. 10.4049\/jimmunol.0901363","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson KV","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019, 19:477-89. 10.1038\/s41577-019-0165-0","journal-title":"Nat Rev Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu X","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016, 535:153-8. 10.1038\/nature18629","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.11.013","article-title":"The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages","volume":"48","author":"Evavold CL","year":"2018","unstructured":"Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity. 2018, 48:35-44.e6. 10.1016\/j.immuni.2017.11.013","journal-title":"Immunity"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki N","year":"2011","unstructured":"Kayagaki N, Warming S, Lamkanfi M, et al.. Non-canonical inflammasome activation targets caspase-11. Nature. 2011, 479:117-21. 10.1038\/nature10558","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou R","year":"2011","unstructured":"Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011, 469:221-5. 10.1038\/nature09663","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti C","year":"2014","unstructured":"Marchetti C, Chojnacki J, Toldo S, et al.. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014, 63:316-22. 10.1097\/FJC.0000000000000053","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis","volume":"36","author":"Shimada K","year":"2012","unstructured":"Shimada K, Crother TR, Karlin J, et al.. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012, 36:401-14. 10.1016\/j.immuni.2012.01.009","journal-title":"Immunity"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo S","year":"2018","unstructured":"Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018, 15:203-14. 10.1038\/nrcardio.2017.161","journal-title":"Nat Rev Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello CA","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018, 281:8-27. 10.1111\/imr.12621","journal-title":"Immunol Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw247","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout GP","year":"2017","unstructured":"van Hout GP, Bosch L, Ellenbroek GH, et al.. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2017, 38:828-36. 10.1093\/eurheartj\/ehw247","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112133","article-title":"MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis","volume":"143","author":"Zhang L","year":"2021","unstructured":"Zhang L, Jiang YH, Fan C, Zhang Q, Jiang YH, Li Y, Xue YT. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed Pharmacother. 2021, 143:112133. 10.1016\/j.biopha.2021.112133","journal-title":"Biomed Pharmacother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti C","year":"2018","unstructured":"Marchetti C, Swartzwelter B, Gamboni F, et al.. OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci U S A. 2018, 115:E1530-9. 10.1073\/pnas.1716095115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif JC","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al.. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019, 381:2497-505. 10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf SM","year":"2020","unstructured":"Nidorf SM, Fiolet AT, Mosterd A, et al.. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020, 383:1838-47. 10.1056\/NEJMoa2021372","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif JC","year":"2021","unstructured":"Tardif JC, Bouabdallaoui N, L'Allier PL, et al.. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet. 2021, 9:924-32. 10.1016\/s2213-2600(21)00222-8","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-018-6781-2","article-title":"The caspase-1 inhibitor VX-765 protects the isolated rat heart via the RISK pathway","volume":"32","author":"Do Carmo H","year":"2018","unstructured":"Do Carmo H, Arjun S, Petrucci O, Yellon DM, Davidson SM. The caspase-1 inhibitor VX-765 protects the isolated rat heart via the RISK pathway. Cardiovasc Drugs Ther. 2018, 32:165-8. 10.1007\/s10557-018-6781-2","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705098","article-title":"Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade","volume":"138","author":"Wang TD","year":"2003","unstructured":"Wang TD, Chen WJ, Mau TJ, Lin JW, Lin WW, Lee YT. Attenuation of increased myocardial ischaemia-reperfusion injury conferred by hypercholesterolaemia through pharmacological inhibition of the caspase-1 cascade. Br J Pharmacol. 2003, 138:291-300. 10.1038\/sj.bjp.0705098","journal-title":"Br J Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0669-6","article-title":"FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation","volume":"21","author":"Hu JJ","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, et al.. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020, 21:736-45. 10.1038\/s41590-020-0669-6","journal-title":"Nat Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.100","article-title":"Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis","volume":"26","author":"Chen X","year":"2016","unstructured":"Chen X, He WT, Hu L, et al.. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016, 26:1007-20. 10.1038\/cr.2016.100","journal-title":"Cell Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction: results from DHART2","volume":"11","author":"Van Tassell BW","year":"2018","unstructured":"Van Tassell BW, Trankle CR, Canada JM, et al.. IL-1 blockade in patients with heart failure with preserved ejection fraction: results from DHART2. Circ Heart Fail. 2018, 11:e005036. 10.1161\/CIRCHEARTFAILURE.118.005036","journal-title":"Circ Heart Fail"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat2738","article-title":"Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis","volume":"3","author":"Rathkey JK","year":"2018","unstructured":"Rathkey JK, Zhao J, Liu Z, et al.. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. 2018, 3:23. 10.1126\/sciimmunol.aat2738","journal-title":"Sci Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017, 377:1119-31. 10.1056\/NEJMoa1707914","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0212-6","article-title":"Pyroptosis versus necroptosis: similarities, differences, and crosstalk","volume":"26","author":"Frank D","year":"2019","unstructured":"Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019, 26:99-114. 10.1038\/s41418-018-0212-6","journal-title":"Cell Death Differ"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab010","article-title":"NLRP3 inflammasome as a key driver of vascular disease","volume":"118","author":"Takahashi M","year":"2022","unstructured":"Takahashi M. NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res. 2022, 118:372-85. 10.1093\/cvr\/cvab010","journal-title":"Cardiovasc Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433265-a-hidden-pathway-to-a-major-concern-the-role-of-pyroptosis-in-inducing-myocardial-infarction-reperfusion-injury-and-emerging-therapeutic-targets","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:49:11Z","timestamp":1764766151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433265-a-hidden-pathway-to-a-major-concern-the-role-of-pyroptosis-in-inducing-myocardial-infarction-reperfusion-injury-and-emerging-therapeutic-targets"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.98370","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}